GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » ROA %

Innovent Biologics (HKSE:01801) ROA % : -1.55% (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Innovent Biologics's annualized Net Income for the quarter that ended in Jun. 2023 was HK$-304 Mil. Innovent Biologics's average Total Assets over the quarter that ended in Jun. 2023 was HK$19,609 Mil. Therefore, Innovent Biologics's annualized ROA % for the quarter that ended in Jun. 2023 was -1.55%.

The historical rank and industry rank for Innovent Biologics's ROA % or its related term are showing as below:

HKSE:01801' s ROA % Range Over the Past 10 Years
Min: -133.05   Med: -19.7   Max: -5.46
Current: -5.46

During the past 8 years, Innovent Biologics's highest ROA % was -5.46%. The lowest was -133.05%. And the median was -19.70%.

HKSE:01801's ROA % is ranked better than
78.21% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs HKSE:01801: -5.46

Innovent Biologics ROA % Historical Data

The historical data trend for Innovent Biologics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics ROA % Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial -25.54 -10.72 -19.70 -12.31 -5.33

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.25 -11.48 -14.23 -1.55 -9.23

Competitive Comparison of Innovent Biologics's ROA %

For the Biotechnology subindustry, Innovent Biologics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's ROA % distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's ROA % falls into.



Innovent Biologics ROA % Calculation

Innovent Biologics's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-2433.623/( (19889.896+19641.722)/ 2 )
=-2433.623/19765.809
=-12.31 %

Innovent Biologics's annualized ROA % for the quarter that ended in Jun. 2023 is calculated as:

ROA %=Net Income (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=-304.396/( (19641.722+19575.43)/ 2 )
=-304.396/19608.576
=-1.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2023) net income data. ROA % is displayed in the 30-year financial page.


Innovent Biologics  (HKSE:01801) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=-304.396/19608.576
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-304.396 / 5909.766)*(5909.766 / 19608.576)
=Net Margin %*Asset Turnover
=-5.15 %*0.3014
=-1.55 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Innovent Biologics ROA % Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines